RxDoctor Payments Data

Gautam Choure, MD

Nephrology · Mesa, AZNPI 1245352574

Payments from drug & device makers

$1,570in general payments, 2019–2025

Across 79 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$298
  • Amgen$265
  • Novartis$226
  • AstraZeneca$223
  • Bayer$160
  • Travere Therapeutics, Inc.$75
  • plus $322 from 10 others

What the payments were for

  • Food & beverage$1,54598%
  • Education$252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,570 in reported general payments places this provider in the 35th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$441,881
Medicare patients
748
Services billed
5,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol34$34,596
LokelmaSodium Zirconium Cyclosilicate21$20,407
Tacrolimus26$3,442
Eplerenone17$2,540
Nifedipine ErNifedipine43$2,264
Sevelamer Carbonate22$2,087
Hydralazine Hcl162$1,957
Mycophenolate Mofetil19$1,921
Amlodipine Besylate188$1,251
Losartan Potassium103$1,050
Potassium Chloride43$983
Furosemide148$946
Valsartan41$865
Allopurinol64$689
Lisinopril75$680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$223$55,00355 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 259 nephrology providers in Arizona.

Other nephrology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →